摘要
Abstract
Objective To observe and evaluate the efficacy and adverse reactions of apatinib for advanced non-small cell lung cancer.Methods A total of 49 patients with advanced non-small cell lung cancer were randomly divided into experimental group and control group from June 2016 to June 2018.The patients in the experimental group received docetaxel 60 mg/m2,dl,and apatinib 500 mg/d,dl-21,3 weeks as a cycle;the patients in the control group received docetaxel chemotherapy only.The levels of cytokeratin 19 fragment (CYFRA21-1),carcinoembryonic antigen (CEA),matrix metalloproteinase-9 (MMP-9),vascular endothelial grow factor (VEGF) were recorded in the two groups.Disease control rate (DCR),progression-free survival (PFS),and the incidence of adverse events were compared between the two groups.Results After treatment,CEA,CYFRA21-1 values in the experimental group were (15.20±1.65),(4.02±0.74) ng/ml,significantly better than those in the control group [(18.09±1.89),(5.85±0.62) ng/ml],with statistically significant differences (P＜0.05).VEGF and MMP-9 values in the experimental group were (275.23±38.98),(1 009.75±179.28) ng/L,better than those in the control group [(486.26±48.38),(1 379.05±179.62) ng/L],with statistically significant differences (P＜0.05).The disease control rate (DCR) were 64.0％ and 33.3％ respectively in the experimental group and the control group;the median PFS were 5.3 months and 3.1 months in the experimental group and the control group,with statistically significant differences (P＜0.05).The experimental group experienced many grade 3-4 hematologic adverse events.Conclusion Apatinib was reliable,and the adverse reactions were mild and well tolerated for advanced non-small cell lung cancer.This treatment could significantly improve the DCR and PFS.关键词
阿帕替尼/晚期非小细胞肺癌/疗效/副作用Key words
Apatinib/Advanced non-small cell lung cancer/Clinical effect/Adverse effects
